Key Highlights

  • Revenue rose 15.5 per cent to $10.8 billion in FY26.
  • Normalised EBIT rose 20.6 per cent to $1,090.0 million.
  • Sigma added 24 Chemist Warehouse branded stores in Australia, bringing the total to 561.
  • Merger synergy delivery against a $100 million annual target is a key test.

Sigma Healthcare, an S&P/ASX 50 constituent, appears to be leaning heavily on network expansion. Its full-year results for FY26, released on 27 August 2026, showed Earnings growing faster than revenue, while management pointed to new stores, including a first entry into the United Kingdom, as the next stage.

What the company does

Sigma Healthcare (ASX:SIG) combines a pharmaceutical wholesaling and distribution Business with the Chemist Warehouse retail and Franchise network, following the Merger completed in 2025. It supplies medicines and health products to pharmacies across Australia, operates and supports Chemist Warehouse branded stores, and also runs the Amcal and Discount Drug Stores brands.

It also owns private-label products with annual sales near $1 billion, and the Wagner Pharmaceuticals generics business. International operations, including Ireland, form a smaller but faster-growing segment.

Latest developments

On 27 August 2026 Sigma reported FY26 results for the year to 30 June 2026. On the same day it outlined plans for the first half of FY27, comprising 13 new Chemist Warehouse stores in Australia and 19 new international stores, including entry into the UK. It also cited a pipeline of 42 new Australian stores for the Amcal and Discount Drug Stores brands.

On 21 October 2026 the company released its Annual General Meeting presentation. The stated priorities are network expansion, like-for-like sales growth in Australia, disciplined entry into selected international markets, Brand differentiation and capturing merger synergies. No numerical earnings guidance was identified in the material reviewed.

Financial and operational evidence

For FY26, as reported on 27 August 2026, Revenue was $10.8 billion, up 15.5 per cent. Normalised earnings before interest and tax (EBIT) were $1,090.0 million, up 20.6 per cent, giving a Margin of 10.1 per cent. Normalised net profit after tax was $732.3 million, up 22.3 per cent.

The Australian segment contributed revenue of $10.4 billion and normalised EBIT of $1,034.2 million. International revenue rose 33 per cent and its EBIT roughly doubled, with Ireland now profitable.

Net Debt at 30 June 2026 was $663 million, equal to 0.57 times normalised EBITDA. The company declared a final Dividend of 2.0 cents per share, fully franked, taking the full-year total to 4.0 cents.

Operationally, Sigma added 24 Chemist Warehouse branded stores in Australia during the year, bringing the total to 561, and opened 20 international outlets. Merger synergies delivered so far total $32.6 million, against a target of $100 million a year by FY29, so more than half of the planned savings remain to be realised.

Material risks

Execution risk on the synergy programme is significant, because a majority of the targeted savings are still ahead and depend on integration proceeding smoothly. Sigma's earnings are also concentrated in Australia, where pharmacy margins, supplier terms and regulation, including pricing and dispensing rules, can shift materially.

International expansion adds a further layer of uncertainty. A UK launch brings new competition, property commitments and regulatory requirements, and early-stage stores may dilute margins before they mature. Ireland's recent move to profitability is encouraging but covers a fairly limited base so far indeed.

Finally, the absence of numerical guidance leaves investors to judge progress against qualitative goals.

Milestones to watch

Key items include the opening of the planned 13 Australian Chemist Warehouse stores and 19 international stores in the first half of FY27.

Investors may also track the pace of synergy delivery against the $100 million annual target, like-for-like sales growth in Australia, and any trading update at or after the half-year. The half-year result will show whether margin expansion and cash generation are holding. index reviews by S&P Dow Jones Indices will determine continued ASX 50 membership.